News

Tamsulosin increases the risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery by more than 50%, according to results of a study published online ahead of print by Acta Ophthalmologica.

Ophthalmologists today are more likely to begin treatment to reduce intraocular pressure (IOP) at lower levels than twenty years ago, according to a study published in the Journal of Glaucoma, August 2008.

Avastin (bevacizumab) is effective in the arrest of angiogenesis at several stages, according to a study published online ahead of print by Acta Ophthalmologica.

MICS: the European picture

Feature includes: statistics providing a true picture of the number of European surgeons practising MICS; interviews with European experts; why you should adopt the technique; product showcase.

Berlin Beckons

Join OTE in booth BL10 at this year's ESCRS congress

Understanding the glaucoma continuum enables earlier detection and better monitoring of the disease, according to Dr Theodore Krupin.

Lucentis gets UK go-ahead

The UK's medical reimbursement governing body, the National Institute for Health and Clinical Excellence (NICE), is to reimburse Lucentis (ranibizumab; Novartis) jointly with Novartis under a dose-capping scheme, reversing NICE's earlier, much derided, decision not to reimburse the drug.

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

By considering geometry, tissue properties and histology, Dr Paul Ernest outlines qualities of a well-constructed wound.

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

Augmenting combined phacoemulsification and deep sclerectomy (PDS) with intraoperative mitomycin C (MMC) is safe and likely to produce lower intraocular pressure (IOP) values than conducting PDS without MMC, according to the results of a study published in the August 2008 issue of Eye.

The Phase II extension study of VEGF Trap-Eye for wet age-related macular degeneration (AMD) has demonstrated extremely favourable results in relation to the primary and key secondary endpoints at the 12-week time point.

Glaucoma patients are at an increased risk of developing ocular surface disease (OSD) in at least one eye, according to a study published in the August 2008 issue of the Journal of Glaucoma.

Control charts are an accurate way of measuring disparity in endophthalmitis following phacoemulsification, according to a study published online ahead of print by Eye.

Paediatric subjects who require frequent steroid therapy are at an increased risk of developing amblyopia due to cataracts, according to a study published online ahead of print by Pediatrics International, the official English language publication of the Japan Pediatric Society.

The protein/peptide patterns in the aqueous humour of primary open-angle glaucoma (POAG) subjects differs significantly from that of control subjects, according to a study published in the August 2008 issue of Molecular Vision.

Defocus curve measurement of subjective amplitude of accommodation (AoA) is not affected by non-randomized letter sequences in presbyopic subjects, according to results of a study published in the August 2008 issue of the Journal of Cataract & Refractive Surgery.

Patients with glaucoma are not at an increased risk of developing systemic vascular disease, according to a study published in the August 2008 issue of the Acta Ophthalmologica.

The incidence of endophthalmitis is independent of whether prophylactic antibiotics are administered in conjunction with Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

The Phase IIb clinical trial of I-vation TA (Merck & Co), an intravitreal injection incorporating triamcinolone acetonide (TA) for the treatment of diabetic macular oedema (DME), has been suspended.